PHARMA SIGNALS.
Model-generated trading signals in the NSE pharma & healthcare universe:
24 liquid derivatives names and 77 curated cash names. Each live signal carries a
direction, an entry reference, an exact close instruction, and a position size for a
$30,000,000 book. Signal families are labelled PH-A … PH-G.
updated 15 Jul 2026, 15:26 IST
Live signalsopen / today · entry ref, close rule, and size for a $30M book
No pharma signals today. The model issued no trade in the pharma / healthcare universe for the latest session (2026-07-15). This is a normal state: signals fire only when the setup is present.
Position size = 3% of book cap ($900k), reduced to 0.5% of the name's
20-day median daily turnover when that is smaller (INR converted at 83.5).
Where a size is liquidity-bound the reason is shown on the card.
Closed tradespharma trades graded in 2026, most recent last · net % and running total
| date | name | side | family | net | cumulative |
|---|
| 2026-07-08 | LUPIN | | PH-A | +1.20% | +1.20% |
| 2026-07-08 | DIVISLAB | | PH-A | +0.55% | +1.75% |
| 2026-07-08 | ALKEM | | PH-A | +1.05% | +2.81% |
| 2026-07-08 | SUNPHARMA | | PH-A | +0.74% | +3.55% |
| 2026-07-08 | CIPLA | | PH-A | +1.43% | +4.98% |
| 2026-07-08 | GLENMARK | | PH-A | +1.66% | +6.64% |
| 2026-07-08 | DRREDDY | | PH-A | +0.34% | +6.98% |
| 2026-07-09 | GUFICBIO | | PH-B | +1.60% | +8.57% |
| 2026-07-09 | INDOCO | | PH-B | +3.59% | +12.17% |
| 2026-07-09 | ADVENZYMES | | PH-B | +1.23% | +13.40% |
| 2026-07-09 | ENTERO | | PH-B | +2.25% | +15.65% |
| 2026-07-09 | PFIZER | | PH-B | +0.03% | +15.68% |
| 2026-07-09 | UNICHEMLAB | | PH-B | +5.74% | +21.42% |
| 2026-07-09 | FDC | | PH-B | +2.10% | +23.51% |
| 2026-07-10 | AUROPHARMA | | PH-A | -0.56% | +22.95% |
| 2026-07-10 | TORNTPHARM | | PH-A | +0.36% | +23.32% |
| 2026-07-10 | CIPLA | | PH-A | -0.05% | +23.26% |
| 2026-07-10 | DRREDDY | | PH-A | +0.03% | +23.29% |
| 2026-07-10 | INDOCO | | PH-B | +1.24% | +24.53% |
| 2026-07-10 | JBCHEPHARM | | PH-B | -1.12% | +23.41% |
| 2026-07-10 | ERIS | | PH-B | +0.41% | +23.83% |
| 2026-07-10 | SAILIFE | | PH-B | +2.34% | +26.17% |
| 2026-07-10 | SOLARA | | PH-B | +0.17% | +26.34% |
| 2026-07-10 | ASTRAZEN | | PH-B | -0.12% | +26.22% |
Forward testsignals published on this site, graded after the fact · since 2026-07-10
This is the honest scoreboard: every signal this site has published, tracked from
issue to close, with nothing removed after the fact. It is separate from the backtest below.
+2.7%
overall (all families)
| issued | closed | name | family | net | equity |
|---|
| 2026-07-10 | 2026-07-10 | AUROPHARMA | PH-A | -0.56% | -0.56% |
| 2026-07-10 | 2026-07-10 | TORNTPHARM | PH-A | +0.36% | -0.20% |
| 2026-07-10 | 2026-07-10 | CIPLA | PH-A | -0.05% | -0.25% |
| 2026-07-10 | 2026-07-10 | DRREDDY | PH-A | +0.03% | -0.22% |
| 2026-07-10 | 2026-07-10 | INDOCO | PH-B | +1.24% | +1.02% |
| 2026-07-10 | 2026-07-10 | JBCHEPHARM | PH-B | -1.12% | -0.10% |
| 2026-07-10 | 2026-07-10 | ERIS | PH-B | +0.41% | +0.31% |
| 2026-07-10 | 2026-07-10 | SAILIFE | PH-B | +2.34% | +2.65% |
| 2026-07-10 | 2026-07-10 | SOLARA | PH-B | +0.17% | +2.82% |
| 2026-07-10 | 2026-07-10 | ASTRAZEN | PH-B | -0.12% | +2.70% |
Track record (backtest)per-family historical record on NSE pharma · simulation, not live results
| PH-A | net % per day traded |
|---|
| 2021 | +0.31 |
| 2022 | +0.44 |
| 2023 | +0.22 |
| 2024 | +0.55 |
| 2025 | +0.27 |
| 2026 | +0.20 |
| years green | 6 of 6 |
| max drawdown | -5.0% |
| PH-B | net % per trade |
|---|
| 2021 | +1.22 |
| 2022 | +0.64 |
| 2023 | +0.95 |
| 2024 | +1.10 |
| 2025 | +1.51 |
| 2026 | +1.02 |
| PH-C | net % per trade |
|---|
| 2021 | -0.06 |
| 2022 | +0.04 |
| 2023 | -0.16 |
| 2024 | +0.22 |
| 2025 | +0.05 |
| 2026 | +0.03 |
| PH-D | net % per trade |
|---|
| headline | +0.39 |
| best window | +0.45 |
| 2026 | +0.09 |
| PH-E | the edge |
|---|
| headline | +1.07% |
| alternate book | +1.39% |
| per unit | +0.23% |
| win rate | 61-65% |
| years green | 6 of 6 |
| PH-F | net % per trade |
|---|
| 2021 | +1.98 |
| 2022 | +0.77 |
| 2023 | +1.25 |
| 2024 | +1.12 |
| 2025 | +1.43 |
| 2026 | +1.36 |
| PH-G | the record |
|---|
| 10-year | +0.70% / event |
| days green | 81% |
| 2026 | +1.5% / event (7 of 7) |
Risk
Position limits. Maximum 3% of book per name ($900k on a $30M book), and never more than
0.5% of a name's 20-day median daily turnover, so a position can be exited without moving the tape.
Daily stop. The book halts new entries after a -3% book day.
Liquidity. Smallcap names are sized by turnover and can be a small fraction of the F&O cap.
Honesty box. These are model outputs, not advice. Entry references are
prices at the signal moment; real fills differ. Backtest figures are simulations with costs applied and are
not a promise of future returns. The forward test above is the only record of live-published performance.
Past performance does not guarantee future results. Probability, not certainty.